
What We’re Reading: Merck COVID-19 Pill Ineffective; Medicaid Use in Prisons; Ozempic in Short Supply
Merck’s COVID-19 pill has been shown to not be successful against household infection risk; the government plans to allow states to use Medicaid funds for prison drug treatment and other services; Ozempic, used to treat type 2 diabetes, is in short supply because it’s being sought for weight loss.
Merck’s COVID Pill Ineffective at Curbing Infection
On Tuesday, Merck & Co said its COVID-19 pill, Lagevrio, was ineffective at reducing SARS-CoV-2 infection risk in individuals living with an infected person,
Prisons, Jails May Soon Use Medicaid for Drug Treatment
The federal government plans to permit states to use their Medicaid funds to provide medication assistance for addiction and other medical services for people in state jails and prisons to try to help those at risk of dying in the midst of the United States overdose epidemic,
Ozempic Scarce Because of Weight Loss Use
Diabetes drug Ozempic is in national shortage because it’s being sought for weight loss,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.